-
The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”
the game," says Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk.
-
Life science trends 2025 – Part 1 obesity drugs
More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obesity has a different mechanism of action, writes Samuel Lagercrantz in the first article in a series of trend insights for 2025. Today: obesity.